|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PLA2G1B |
Gene summary for PLA2G1B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PLA2G1B | Gene ID | 5319 |
| Gene name | phospholipase A2 group IB | |
| Gene Alias | PLA2 | |
| Cytomap | 12q24.31 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P04054 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5319 | PLA2G1B | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 4.31e-13 | 8.09e-01 | -0.2116 |
| 5319 | PLA2G1B | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.03e-11 | 9.09e-01 | -0.2119 |
| 5319 | PLA2G1B | HTA12-15-2 | Human | Pancreas | PDAC | 7.05e-47 | -2.37e+00 | 0.2315 |
| 5319 | PLA2G1B | HTA12-18-3 | Human | Pancreas | PDAC | 1.72e-03 | -2.42e-01 | 0.0716 |
| 5319 | PLA2G1B | HTA12-23-1 | Human | Pancreas | PDAC | 1.05e-31 | -2.48e+00 | 0.3405 |
| 5319 | PLA2G1B | HTA12-25-1 | Human | Pancreas | PDAC | 2.82e-44 | -2.48e+00 | 0.313 |
| 5319 | PLA2G1B | HTA12-26-1 | Human | Pancreas | PDAC | 4.40e-53 | -2.48e+00 | 0.3728 |
| 5319 | PLA2G1B | HTA12-29-1 | Human | Pancreas | PDAC | 4.52e-121 | -2.48e+00 | 0.3722 |
| 5319 | PLA2G1B | HTA12-3-16 | Human | Pancreas | PDAC | 7.55e-11 | -2.48e+00 | 0.1553 |
| 5319 | PLA2G1B | HTA12-30-1 | Human | Pancreas | PDAC | 4.13e-12 | -2.48e+00 | 0.3671 |
| 5319 | PLA2G1B | HTA12-32-1 | Human | Pancreas | PDAC | 6.22e-17 | -2.48e+00 | 0.3624 |
| 5319 | PLA2G1B | HTA12-9-1 | Human | Pancreas | PDAC | 1.66e-68 | -2.38e+00 | 0.1532 |
| 5319 | PLA2G1B | HTA12-9-2 | Human | Pancreas | PDAC | 7.77e-12 | -3.05e-01 | 0.0835 |
| 5319 | PLA2G1B | HTA12-9-3 | Human | Pancreas | PDAC | 2.61e-37 | -2.48e+00 | 0.2045 |
| 5319 | PLA2G1B | 3829-EC | Human | Pancreas | PanIN | 1.42e-43 | -2.16e-01 | 0.009 |
| 5319 | PLA2G1B | 4347-EC | Human | Pancreas | PanIN | 1.21e-34 | -3.31e-01 | 0.0572 |
| 5319 | PLA2G1B | 181429 | Human | Pancreas | PDAC | 2.41e-20 | -2.48e+00 | 0.1416 |
| 5319 | PLA2G1B | 61354830 | Human | Pancreas | PDAC | 4.13e-12 | -2.48e+00 | 0.1458 |
| 5319 | PLA2G1B | DS20191261Tumor | Human | Pancreas | PDAC | 3.21e-82 | -2.48e+00 | 0.1367 |
| 5319 | PLA2G1B | DS20191261TumorKeller | Human | Pancreas | PDAC | 1.04e-25 | -2.48e+00 | 0.1407 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000701513 | Lung | AIS | actin filament organization | 88/1849 | 442/18723 | 1.02e-10 | 3.13e-08 | 88 |
| GO:003286812 | Lung | AIS | response to insulin | 52/1849 | 264/18723 | 9.51e-07 | 6.69e-05 | 52 |
| GO:190165312 | Lung | AIS | cellular response to peptide | 65/1849 | 359/18723 | 1.05e-06 | 7.27e-05 | 65 |
| GO:007137512 | Lung | AIS | cellular response to peptide hormone stimulus | 55/1849 | 290/18723 | 1.62e-06 | 9.91e-05 | 55 |
| GO:003286912 | Lung | AIS | cellular response to insulin stimulus | 42/1849 | 203/18723 | 2.80e-06 | 1.52e-04 | 42 |
| GO:003367412 | Lung | AIS | positive regulation of kinase activity | 77/1849 | 467/18723 | 4.67e-06 | 2.31e-04 | 77 |
| GO:004343413 | Lung | AIS | response to peptide hormone | 70/1849 | 414/18723 | 5.19e-06 | 2.48e-04 | 70 |
| GO:004586012 | Lung | AIS | positive regulation of protein kinase activity | 65/1849 | 386/18723 | 1.27e-05 | 4.78e-04 | 65 |
| GO:007190012 | Lung | AIS | regulation of protein serine/threonine kinase activity | 61/1849 | 359/18723 | 1.76e-05 | 6.17e-04 | 61 |
| GO:007190211 | Lung | AIS | positive regulation of protein serine/threonine kinase activity | 38/1849 | 200/18723 | 6.00e-05 | 1.65e-03 | 38 |
| GO:00434101 | Lung | AIS | positive regulation of MAPK cascade | 72/1849 | 480/18723 | 2.11e-04 | 4.32e-03 | 72 |
| GO:00512228 | Lung | AIS | positive regulation of protein transport | 49/1849 | 303/18723 | 3.78e-04 | 6.61e-03 | 49 |
| GO:004340511 | Lung | AIS | regulation of MAP kinase activity | 32/1849 | 177/18723 | 5.53e-04 | 8.71e-03 | 32 |
| GO:00481451 | Lung | AIS | regulation of fibroblast proliferation | 18/1849 | 80/18723 | 6.68e-04 | 1.00e-02 | 18 |
| GO:00481441 | Lung | AIS | fibroblast proliferation | 18/1849 | 81/18723 | 7.81e-04 | 1.11e-02 | 18 |
| GO:00510921 | Lung | AIS | positive regulation of NF-kappaB transcription factor activity | 28/1849 | 152/18723 | 8.81e-04 | 1.19e-02 | 28 |
| GO:005109011 | Lung | AIS | regulation of DNA-binding transcription factor activity | 64/1849 | 440/18723 | 1.04e-03 | 1.36e-02 | 64 |
| GO:19049518 | Lung | AIS | positive regulation of establishment of protein localization | 49/1849 | 319/18723 | 1.21e-03 | 1.54e-02 | 49 |
| GO:005109111 | Lung | AIS | positive regulation of DNA-binding transcription factor activity | 41/1849 | 260/18723 | 1.77e-03 | 2.01e-02 | 41 |
| GO:001095912 | Lung | AIS | regulation of metal ion transport | 58/1849 | 406/18723 | 2.63e-03 | 2.67e-02 | 58 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PLA2G1B | SNV | Missense_Mutation | novel | c.406N>A | p.Ala136Thr | p.A136T | P04054 | protein_coding | tolerated(0.07) | benign(0.041) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PLA2G1B | SNV | Missense_Mutation | novel | c.46G>C | p.Asp16His | p.D16H | P04054 | protein_coding | tolerated(0.08) | benign(0.087) | TCGA-VS-A9UY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| PLA2G1B | SNV | Missense_Mutation | c.20N>T | p.Ala7Val | p.A7V | P04054 | protein_coding | tolerated(0.44) | probably_damaging(0.991) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| PLA2G1B | SNV | Missense_Mutation | novel | c.28C>A | p.Leu10Ile | p.L10I | P04054 | protein_coding | tolerated(0.06) | probably_damaging(0.987) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PLA2G1B | SNV | Missense_Mutation | novel | c.251A>C | p.Lys84Thr | p.K84T | P04054 | protein_coding | tolerated(0.55) | benign(0.015) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| PLA2G1B | SNV | Missense_Mutation | rs778999608 | c.53N>A | p.Gly18Asp | p.G18D | P04054 | protein_coding | tolerated(0.51) | benign(0) | TCGA-BC-A69I-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| PLA2G1B | SNV | Missense_Mutation | c.10N>A | p.Leu4Ile | p.L4I | P04054 | protein_coding | tolerated(0.1) | benign(0.014) | TCGA-55-7728-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PLA2G1B | SNV | Missense_Mutation | c.439N>A | p.Gln147Lys | p.Q147K | P04054 | protein_coding | tolerated(1) | benign(0) | TCGA-86-8358-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| PLA2G1B | SNV | Missense_Mutation | novel | c.115N>A | p.Asp39Asn | p.D39N | P04054 | protein_coding | tolerated(0.36) | benign(0.003) | TCGA-VQ-A91K-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | CR |
| PLA2G1B | SNV | Missense_Mutation | novel | c.107N>A | p.Pro36Gln | p.P36Q | P04054 | protein_coding | deleterious(0) | probably_damaging(0.963) | TCGA-E8-A2EA-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5319 | PLA2G1B | PHOSPHOLIPASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | MPA | PROGESTERONE | 7872957 | |
| 5319 | PLA2G1B | PHOSPHOLIPASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | MRX-4 | CONTEZOLID ACEFOSAMIL | ||
| 5319 | PLA2G1B | PHOSPHOLIPASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | CHOLIC ACID | CHOLIC ACID | 19102680 | |
| 5319 | PLA2G1B | PHOSPHOLIPASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | BIFONAZOLE | BIFONAZOLE | ||
| 5319 | PLA2G1B | PHOSPHOLIPASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | RANITIDINE | RANITIDINE | 10383521 | |
| 5319 | PLA2G1B | PHOSPHOLIPASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | NIFLUMIC ACID | |||
| 5319 | PLA2G1B | PHOSPHOLIPASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | TOLFENAMIC ACID | TOLFENAMIC ACID | ||
| 5319 | PLA2G1B | PHOSPHOLIPASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | Clobetasol | CLOBETASOL | ||
| 5319 | PLA2G1B | PHOSPHOLIPASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | inhibitor | 252827445 | ||
| 5319 | PLA2G1B | PHOSPHOLIPASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | ETOPOSIDE | ETOPOSIDE | 9716508 |
| Page: 1 2 3 4 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |